Comparison of botulinum neurotoxin type A formulations in Asia

RESULTS: All protein-based therapeutics, such as botulinum neurotoxin type A (BoNT/A), are potentially immunogenic and can lead to anaphylaxis, autoimmunity, or diminished or complete absence of therapeutic efficacy, especially if administered repeatedly. Therefore, the protein quantity in BoNT/A pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Frevert, Jürgen, Ahn, Ki Young, Park, Mee Young, Sunga, Owen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039073/
https://www.ncbi.nlm.nih.gov/pubmed/30013379
http://dx.doi.org/10.2147/CCID.S160723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039073/
https://www.ncbi.nlm.nih.gov/pubmed/30013379
http://dx.doi.org/10.2147/CCID.S160723

Ejemplares similares